Coonley C J, Schauer P, Kelsen D P, Sordillo P, Huvos A G
Am J Clin Oncol. 1985 Aug;8(4):307-11. doi: 10.1097/00000421-198508000-00006.
Sweat gland carcinoma (SGC) is a rare malignancy of the skin. though many patients with SGC die of disseminated metastases, little is known regarding the value of systemic chemotherapy for this disease. We reviewed the records of 20 patients with metastatic SGC who were treated with chemotherapy at Memorial Hospital between 1968 and 1983. A large variety of drugs were given. Although only a few patients were treated with any given regimen, metastatic SGC appears to be poorly responsive to a wide variety of chemotherapeutic regimens. Five major responses were observed in 30 chemotherapy trials performed in 17 patients with measurable/evaluable disease. No patient responded to single agent therapy alone. In this small group of patients, SGC appears to be a relatively chemotherapy resistant tumor. Larger, group-wide or inter-group trials are needed to prospectively evaluate the use of chemotherapy in this disease. Doxorubicin and cyclophosphamide, the two drugs used most commonly in those combinations where responses were seen, appear to be reasonable choices for initial treatment of patients with metastatic disease. Our review does not provide data to support the empiric use of chemotherapy in an adjuvant setting.
汗腺癌（SGC）是一种罕见的皮肤恶性肿瘤。尽管许多汗腺癌患者死于广泛转移，但对于这种疾病的全身化疗价值却知之甚少。我们回顾了1968年至1983年间在纪念医院接受化疗的20例转移性汗腺癌患者的记录。使用了各种各样的药物。尽管只有少数患者接受了任何特定方案的治疗，但转移性汗腺癌似乎对多种化疗方案反应不佳。在对17例可测量/可评估疾病患者进行的30次化疗试验中观察到5例主要缓解。没有患者仅对单药治疗有反应。在这一小群患者中，汗腺癌似乎是一种相对化疗耐药的肿瘤。需要进行更大规模的全组或组间试验，以前瞻性评估化疗在这种疾病中的应用。阿霉素和环磷酰胺是在出现缓解的联合用药中最常用的两种药物，似乎是转移性疾病患者初始治疗的合理选择。我们的综述没有提供数据支持在辅助治疗中经验性使用化疗。
